2 million (39.81%) for unrealized gain in 
2019. IBA has no capital commitments as at December 
31, 2022 and December 31, 2023 to participate 
in any potential future funding of Normandy 
Hadrontherapy SAS. IBA has therefore not accounted for its share of 
the loss and negative equity of Normandy 
Hadrontherapy SAS beyond its value of the 
capital invested. The following table illustrates the summarized financial information of the associates: (EUR 000) 
December 31, 2022 
December 31, 2023 
In